LYELL IMMUNOPHARMA
Lyell is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell focuses on addressing what it believes are the primary barriers that limit consistent, reliable and curative responses with adoptive T cell therapy: T cell exhaustion and loss of durable stemness, which includes proliferative capacity, ability to self-renew and ability to differentiate and eliminate solid tumors. Lyell is applying its proprietary ex vivo genetic and epigenetic reprogramming technology platforms, Gen-R and Epi-R, to address these barriers in order to develop new medicines with improved, durable, and potentially curative clinical outcomes.
LYELL IMMUNOPHARMA
Social Links:
Industry:
Biotechnology Health Care Medical Pharmaceutical
Founded:
2018-01-01
Status:
Active
Contact:
1 650-695-0677
Total Funding:
493 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Content Delivery Network Mobile Non Scaleable Content Nginx Amazon IPv6
Similar Organizations
Adyn
Adyn is a precision medicine company that develops personalized birth control methods.
Rakuten Medical
Rakuten Medical is a Bio-technology Company.
Cerespir
Cerespir is an operator of a biotechnology company intended to treat neurodegenerative disorders.
Day One Biopharmaceuticals
Day One Biopharmaceuticals is a biotechnology company that focuses on developing new cancer therapies for patients of all ages.
ESSA Pharma
ESSA Pharma is a biotechnology company that develops new drugs for prostate cancer.
Instil Bio
Instil Bio is a biotechnology company that develops cell therapies for solid tumor cures.
Kallyope
Kallyope is a biotechnology company dedicated to unlocking the therapeutic potential of the gut-brain axis.
Lineage Cell Therapeutics
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cellular therapies to treat unmet medical needs.
Moderna Therapeutics
Moderna Therapeutics is a biotechnology company that specializes in drug discovery and drug development based on messenger RNA.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
Nutcracker Therapeutics
Nutcracker Therapeutics is a biotech company that develops mRNA therapeutics.
Olema Oncology
Olema Oncology is a preclinical biotechnology company that develops new drugs for the treatment and prevention of breast cancer.
Outpace Bio
Outpace Bio is a biotechnology company that creates smart cell therapies aimed at improving efficacy and safety.
PanTheryx
PanTheryx is a nutrition and biotechnology company that utilizes the cellular and biomolecular processes of bovine colostrum.
PocketPills
Pocketpills is Canada's leading online pharmacy, delivers medication by the dose, straight to customer's door.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
The Public Health Company
The Public Health Company is a biotechnology firm that offers a platform for genomic epidemiology scientists to outbreak intelligence.
Toregem BioPharma
Toregem BioPharma is a startup from Kyoto University that develops a treatment for congenital adentia.
Triumvira Immunologics
Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer.
Vor Biopharma
Vor Biopharma is an immuno-oncology company that develops therapies for treating cancer.
Current Employees Featured
Founder
Stock Details
Investors List
Sahsen Ventures
Sahsen Ventures investment in Series A - Lyell Immunopharma
Bill & Melinda Gates Foundation
Bill & Melinda Gates Foundation investment in Series A - Lyell Immunopharma
ARCH Venture Partners
ARCH Venture Partners investment in Series A - Lyell Immunopharma
Arrive
Arrive investment in Series A - Lyell Immunopharma
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-03-31 | Outpace Bio | Lyell Immunopharma investment in Series A - Outpace Bio | 30 M USD |
| 2020-09-30 | Sonoma Pharmaceuticals | Lyell Immunopharma investment in Post-IPO Equity - Sonoma Pharmaceuticals | 70 M USD |
| 2020-09-30 | Sonoma BioTherapeutics | Lyell Immunopharma investment in Series A - Sonoma BioTherapeutics | 30 M USD |
| 2020-03-18 | Cero Therapeutics | Lyell Immunopharma investment in Series A - Cero Therapeutics | 40 M USD |
| 2020-03-17 | Eureka Therapeutics | Lyell Immunopharma investment in Series E - Eureka Therapeutics | 45 M USD |
| 2020-02-06 | Sonoma BioTherapeutics | Lyell Immunopharma investment in Series A - Sonoma BioTherapeutics | 40 M USD |
Key Employee Changes
| Date | New article |
|---|---|
| 2022-01-31 | Lyell Immunopharma Appoints Gary Lee, Ph.D. as Chief Scientific Officer |